China Launches Trial Medical Device Vigilance Framework Across 17 Pilot Regions

In April 2026, China’s National Adverse Drug Reaction Monitoring Center, approved by the National Medical Products Administration (NMPA), released five trial documents establishing the country’s first coordinated medical device vigilance framework. The documents introduce formal requirements for vigilance management, inspections, vigilance plans, periodic safety update reports (PSURs), and trend reports. 

The framework entered trial implementation on April 13, 2026, across 17 pilot provinces and municipalities, including Beijing, Shanghai, Hainan, Zhejiang, Guangdong, and Sichuan. 

For foreign manufacturers, the framework signals a more structured and inspection-driven approach to post-market surveillance, with clearer expectations around reporting, oversight, and local compliance responsibilities. 

At a Glance: What the New Framework Means 

• Implements formal vigilance quality management system requirements  
• Expands expectations for PSURs, trend reports, and vigilance planning  
• Heightens scrutiny during regulatory inspections  
• Increases coordination requirements between overseas manufacturers and China agents  
• Enhances China-specific vigilance procedures and documentation 

Companies operating in the pilot regions should begin assessing compliance gaps now and prepare for possible nationwide implementation — contact Cisema today for support. 

The Five Trial Documents: A Unified Vigilance Framework 

The five documents collectively establish an integrated system covering post-market monitoring, reporting obligations, and regulatory oversight: 

• Medical Device Vigilance Management (Trial) 
• Key Points for Medical Device Vigilance Inspections (Trial) 
• Guidelines for Drafting Medical Device Trend Reports (Trial) 
• Guidelines for Drafting Periodic Safety Update Reports for Medical Devices (Trial) 
• Guidelines for Drafting Medical Device Vigilance Plans (Trial) 

Together, the documents outline how registrants and filing entities are expected to manage vigilance activities, maintain supporting records, evaluate safety information, and support regulatory oversight. 

Medical Device Vigilance Management (Trial) 

This document establishes the foundational requirements for vigilance management in China. Registrants and filing entities must establish and maintain systems that support ongoing monitoring and post-market compliance activities. 

The requirements address: 

• Organizational structure 
• Personnel responsibilities 
• Internal systems and procedures 
• Operational controls for vigilance activities 

For overseas manufacturers, this requires closer alignment between global vigilance procedures and China-specific regulatory requirements. Companies should also ensure that responsibilities between the foreign manufacturer and the China agent are clearly documented and reflected in internal procedures. 

Key Points for Medical Device Vigilance Inspections (Trial) 

This document provides regulators with standardized inspection criteria for reviewing vigilance systems and related activities. 

Companies should be prepared to demonstrate that key processes are documented, implemented, and consistently maintained. Relevant records may include: 

• Vigilance SOPs  
• Training records  
• Report templates  
• Completed vigilance reports  
• Internal review documentation  
• China agent communication records  
• Corrective and preventive action documentation  

The guidance suggests regulators will place greater emphasis on operational traceability and inspection readiness during post-market oversight activities. 

Guidelines for Drafting Medical Device Trend Reports (Trial) 

This document establishes requirements for preparing trend reports intended to identify and assess emerging safety patterns. 

To support these reporting obligations, companies should confirm that complaint handling, adverse event monitoring, and data analysis procedures can generate reliable and well-documented trend data for the Chinese market. 

In practice, this may require closer coordination between global safety teams, local regulatory personnel, and China representatives responsible for post-market activities. 

Guidelines for Drafting Periodic Safety Update Reports for Medical Devices (Trial) 

This document defines requirements for periodic safety update reports, including their structure, content, format, and submission expectations. 

Companies should assess whether existing global reports satisfy China-specific requirements or whether supplemental local reporting will be needed. 

Where global documentation does not fully align with Chinese expectations, companies may need to prepare additional China-focused analyses or reporting sections. 

Guidelines for Drafting Medical Device Vigilance Plans (Trial) 

This document outlines expectations for preparing vigilance plans that describe how ongoing monitoring activities will be organized and maintained. 

The plans are intended to support consistent implementation of post-market obligations and provide regulators with clearer visibility into how manufacturers manage vigilance responsibilities over time. 

Companies should review whether existing post-market surveillance plans can be adapted for China or whether separate local procedures and documentation will be needed. 

Trial Implementation Covers 17 Key Chinese Regions 

The framework is initially being implemented across 17 provinces and municipalities. The pilot scope includes several of China’s major commercial, manufacturing, and regulatory centers: 

1. Beijing 
2. Hebei 
3. Shanxi 
4. Liaoning 
5. Shanghai 
6. Jiangsu 
7. Zhejiang 
8. Fujian
9. Jiangxi
10. Shandong
11. Henan
12. Guangdong
13. Guangxi
14. Hainan
15. Chongqing
16. Sichuan
17. Guizhou 

This pilot phase allows regulators to refine implementation before potential nationwide rollout. For manufacturers already active in China, particularly in these regions, the implications are immediate. 

Compliance Priorities for Foreign Medical Device Companies 

The new framework introduces greater operational clarity around medical device vigilance expectations in China while also increasing reporting, governance, and inspection responsibilities for foreign manufacturers. 

Companies should compare the new trial requirements against existing internal procedures and identify gaps in oversight, reporting workflows, inspection readiness, and local coordination practices. 

Recommended preparation activities include: 

• Review existing vigilance SOPs against the new Chinese trial requirements.  
• Establish or update a medical device vigilance quality management system.  
• Develop internal procedures for vigilance plans, PSURs, and trend reports.  
• Train regulatory, quality, and post-market surveillance personnel.  
• Monitor pilot-region implementation and prepare for possible nationwide expansion.  

Early preparation may help reduce compliance risk and support smoother adaptation as China’s post-market regulatory framework continues to develop. 

Final Thoughts: Preparing for China’s Evolving Vigilance Requirements 

China’s new trial medical device vigilance framework marks a clear shift toward more structured and inspection-focused post-market oversight. With new expectations for vigilance management, PSURs, trend reports, inspections, and vigilance plans, overseas manufacturers should expect increased compliance and documentation requirements. 

For international medical device companies, the challenge is aligning global post-market surveillance systems with China-specific regulatory expectations. Differences in reporting formats, documentation standards, and local responsibilities may require significant procedural and operational adjustments. 

To support this transition, Cisema can help companies interpret the new trial vigilance documents, assess compliance impact, revise vigilance SOPs, align local processes, and prepare required reports for pilot-region implementation. 

Contact Cisema today to assess readiness for China’s evolving medical device vigilance requirements. 

Further Information 

• Explore Cisema’s services for medical device registration in China 

References 

• Medical Device Vigilance Management (Trial) 
• Key Points for Medical Device Vigilance Inspections (Trial) 
• Guidelines for Drafting Medical Device Trend Reports (Trial) 
• Guidelines for Drafting Periodic Safety Update Reports for Medical Devices (Trial) 
• Guidelines for Drafting Medical Device Vigilance Plans (Trial)